|
|
|
|
|
|
|
Highlights from the 2024 American Society For Radiation Oncology Annual Meeting |
|
|
|
|
| Pembrolizumab Monotherapy Following Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer
|
| Shang-Bin Qin, MD
|
| In this Phase 2 trial, Dr. Shang-Bin Qin evaluates the use of Pembrolizumab as maintenance therapy following trimodal therapy with a SABR boost in patients with MIBC who achieved a complete response. With a median follow-up of 10 months, 85% of patients remained progression-free, and 93% maintained local control. Pembrolizumab was well-tolerated, though immune-related adverse events were reported in 24% of patients, supporting the efficacy and safety of this approach in bladder preservation.
|
|
|
|
|
|
| Bi-Institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer
|
| Yash Soni, MD
|
| Yash Soni evaluated the safety of combining enfortumab vedotin (EV) and radiotherapy (RT) in patients with advanced urothelial cancer. Among 60 patients treated with EV and palliative RT, EV discontinuation occurred in 23% of cases due to toxicities, primarily neuropathy and skin reactions, though none were attributed to RT.
|
|
|
|
|
|
| Pathologic Features of Small Cell Variants of the Genitourinary Tract
|
| Hikmat Al-Ahmadie, MD
|
| Hikmat Al-Ahmadie presents on the pathologic features of small cell variants of the genitourinary tract, particularly focusing on small cell neuroendocrine carcinomas of the bladder and prostate. Small cell carcinomas in these organs are pathologically similar to those found in the lung and often present at advanced stages with a poor prognosis.
|
|
|
|
|
|
|
|
|
|
|
| Emerging Systemic Therapy and Trials for Small Cell Cancer of the Genitourinary Tract |
| Jean Hoffman-Censits, MD |
| Jean Hoffman-Censits discusses emerging systemic therapies and clinical trials for small-cell cancers of the genitourinary tract, which are rare and aggressive. Treatment is often guided by protocols for small-cell lung cancer, with platinum-based chemotherapy improving survival. However, there are limited data on checkpoint inhibitors, with mixed outcomes for newer agents like lurbinectedin and trastuzumab deruxtecan. |
|
|
|
|
|
| Radiation Therapy for Small Cell Bladder Cancers
|
| Vedang Murthy, MD, DNB, DipEPP
|
| Vedang Murthy presents on radiation therapy (RT) for small cell bladder cancers, focusing on treatment strategies for a high-risk case: a 53-year-old female with 95% small cell carcinoma and 5% urothelial carcinoma (T3N1M0 staging). Dr. Murthy highlighted that neoadjuvant chemotherapy, such as cisplatin and etoposide, is generally preferred for small cell variants, as it significantly improves survival compared to surgery alone.
|
|
|
|
|
|
| Role of Surgery in the Management of Genitourinary Small Cell Tumors
|
| Nima Almassi, MD
|
| Nima Almassi discusses the role of surgery in managing genitourinary small-cell tumors, highlighting the importance of TURBT for diagnosis and symptom palliation. He emphasized that bladder neuroendocrine carcinoma is often locally advanced at diagnosis, and radical cystectomy alone is rarely curative. However, surgery can play a role in consolidative treatment, particularly for managing severe symptoms and assessing residual disease. Multidisciplinary evaluation and careful pathology review are crucial for optimizing outcomes.
|
|
|
|
|
|
| Radiation Therapy for Small Cell Neuroendocrine Tumors of the Genitourinary Tract
|
| Emily Weg, MD
|
| Emily Weg discusses the role of radiation therapy in managing small-cell neuroendocrine tumors of the genitourinary tract, particularly focusing on prostate small-cell carcinoma. This rare cancer often presents with advanced disease and metastasis, with poor survival rates. Chemotherapy improves survival in node-positive and metastatic cases, and radiotherapy provides symptomatic relief and local control for advanced disease.
|
|
|
|
|
|
|
|
|
|
|
